Early approaches of YKL-40 as a biomarker and therapeutic target for Parkinson's disease
Neurodegenerative Disease Management, ISSN: 1758-2032, Vol: 13, Issue: 2, Page: 85-99
2023
- 12Citations
- 7Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations12
- Citation Indexes12
- 12
- CrossRef7
- Captures7
- Readers7
- Mentions1
- News Mentions1
- News1
Most Recent News
Early approaches of YKL-40 as a biomarker and therapeutic target for Parkinson's disease.
Neurodegener Dis Manag. 2023 Jan 16; Authors: Anwar MM, Fathi MH PubMed: 36644988 Submit Comment
Article Description
Aim: To investigate whether the estimation of cerebrospinal fluid (CSF) and brain YKL-40 levels may be used as an efficient biomarker for Parkinson's disease (PD). Methods: Lipopolysaccharides (LPS) was injected into the right substantia nigra pars compacta (SNpc). Rats were divided into: control group, early LPS-induced PD group (14 days), and advanced LPS-induced PD group (28 days). YKL-40 and other related factors were detected in CSF and brain tissue. Results: Increased expression of YKL-40 was observed in brain tissue and CSF of PD-induced rats associated with triggered inflammatory cytokine release. Conclusion: The current study was limited to detecting YKL-40 and other inflammatory factors in brain and CSF. YKL-40 may be considered as an early biomarker and therapeutic target for PD. Plain language summary Parkinson's disease (PD) is one of the most devastating fast-spreading neurological disorders with a high prevalence and incidence of death. Progress in developing efficient therapeutic interventions in PD may only be achieved through reliable early diagnostic approaches along with regular monitoring of PD progression. Although the current clinical diagnostic approach to PD relies mainly on late motor symptoms, the rate of misdiagnosis is considered high due to the overlap of PD with other etiologies. Novel and reliable biological biomarkers are highly required among researchers with the aim of early detection of the disease pathogenesis during the premotor stages to avoid debilitating PD stages. Thereby, identifying and highlighting novel biological biomarkers are highly required in the early diagnosis of neurological disorders.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85160796572&origin=inward; http://dx.doi.org/10.2217/nmt-2022-0010; http://www.ncbi.nlm.nih.gov/pubmed/36644988; https://www.tandfonline.com/doi/full/10.2217/nmt-2022-0010; https://dx.doi.org/10.2217/nmt-2022-0010; https://www.futuremedicine.com/doi/10.2217/nmt-2022-0010
Informa UK Limited
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know